Controlling Nutritional Status (CONUT) as a predictor of survival and complications among colorectal cancer patients: A systematic review and meta-analysis

IF 2.9 3区医学 Q2 GASTROENTEROLOGY & HEPATOLOGY

Colorectal Disease Pub Date : 2025-05-19 DOI:10.1111/codi.70120

Akhil Deepak Vatvani, Pratik Patel, Dhienda Cempaka Shahannaz, Theo Audi Yanto, Timotius Ivan Hariyanto

{"title":"Controlling Nutritional Status (CONUT) as a predictor of survival and complications among colorectal cancer patients: A systematic review and meta-analysis","authors":"Akhil Deepak Vatvani, Pratik Patel, Dhienda Cempaka Shahannaz, Theo Audi Yanto, Timotius Ivan Hariyanto","doi":"10.1111/codi.70120","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Aim</h3>\n \n <p>The Controlling Nutritional Status (CONUT) scoring system integrates components of inflammation and nutrition, both of which significantly influence cancer progression. However, its utility in colorectal cancer remains ambiguous and contradictory. The aim of this study is to evaluate the efficacy of the CONUT score in forecasting the prognosis of colorectal cancer patients.</p>\n </section>\n \n <section>\n \n <h3> Method</h3>\n \n <p>A thorough search was performed on the Scopus, Medline, Europe PMC and Cochrane Library databases up to 18 November 2024. This review includes evidence that investigates the correlation between the CONUT score and outcomes in colorectal cancer patients. We utilized random-effects models to evaluate the hazard ratio (HR) for the occurrence of the outcomes.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>A total of 22 papers were included in the systematic review, with 20 of them included in the meta-analysis. The pooled analysis from multivariable data revealed that a high CONUT score was an independent predictor of poor overall survival (HR 2.02, 95% CI 1.74–2.34, <i>p</i> < 0.00001), disease-free survival (HR 2.96, 95% CI 1.28–6.85, <i>p</i> = 0.01), cancer-specific survival (HR 3.93, 95% CI 2.16–7.15, <i>p</i> < 0.00001) and recurrence-free survival (HR 1.76, 95% CI 1.42–2.19, <i>p</i> < 0.00001) among colorectal cancer patients. A high CONUT score was also correlated with a greater likelihood of postoperative complications than a low CONUT score in colorectal cancer patients (HR 2.04, 95% CI 1.44–2.89, <i>p</i> < 0.0001).</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>This study suggests the prognostic capability of the CONUT score in forecasting the short- and long-term outcomes of colorectal cancer patients; it therefore can be routinely calculated to stratify the risk of patients.</p>\n </section>\n </div>","PeriodicalId":10512,"journal":{"name":"Colorectal Disease","volume":"27 5","pages":""},"PeriodicalIF":2.9000,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Colorectal Disease","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/codi.70120","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Aim

The Controlling Nutritional Status (CONUT) scoring system integrates components of inflammation and nutrition, both of which significantly influence cancer progression. However, its utility in colorectal cancer remains ambiguous and contradictory. The aim of this study is to evaluate the efficacy of the CONUT score in forecasting the prognosis of colorectal cancer patients.

Method

A thorough search was performed on the Scopus, Medline, Europe PMC and Cochrane Library databases up to 18 November 2024. This review includes evidence that investigates the correlation between the CONUT score and outcomes in colorectal cancer patients. We utilized random-effects models to evaluate the hazard ratio (HR) for the occurrence of the outcomes.

Results

A total of 22 papers were included in the systematic review, with 20 of them included in the meta-analysis. The pooled analysis from multivariable data revealed that a high CONUT score was an independent predictor of poor overall survival (HR 2.02, 95% CI 1.74–2.34, p < 0.00001), disease-free survival (HR 2.96, 95% CI 1.28–6.85, p = 0.01), cancer-specific survival (HR 3.93, 95% CI 2.16–7.15, p < 0.00001) and recurrence-free survival (HR 1.76, 95% CI 1.42–2.19, p < 0.00001) among colorectal cancer patients. A high CONUT score was also correlated with a greater likelihood of postoperative complications than a low CONUT score in colorectal cancer patients (HR 2.04, 95% CI 1.44–2.89, p < 0.0001).

Conclusions

This study suggests the prognostic capability of the CONUT score in forecasting the short- and long-term outcomes of colorectal cancer patients; it therefore can be routinely calculated to stratify the risk of patients.

查看原文本刊更多论文

控制营养状况（CONUT）作为结直肠癌患者生存和并发症的预测因子：一项系统综述和荟萃分析

控制营养状态（CONUT）评分系统集成了炎症和营养的组成部分，两者都显著影响癌症的进展。然而，它在结直肠癌中的应用仍然是模糊和矛盾的。本研究的目的是评估CONUT评分在预测结直肠癌患者预后方面的有效性。方法对截至2024年11月18日的Scopus、Medline、Europe PMC和Cochrane Library数据库进行全面检索。本综述包括调查结直肠癌患者CONUT评分与预后之间相关性的证据。我们使用随机效应模型来评估结果发生的风险比（HR）。结果系统评价共纳入22篇论文，其中20篇纳入meta分析。多变量数据的汇总分析显示，高CONUT评分是结直肠癌患者总生存率（HR 2.02, 95% CI 1.74-2.34, p < 0.00001）、无病生存率（HR 2.96, 95% CI 1.28-6.85, p = 0.01）、癌症特异性生存率（HR 3.93, 95% CI 2.16-7.15, p < 0.00001）和无复发生存率（HR 1.76, 95% CI 1.42-2.19, p < 0.00001）较差的独立预测因子。在结直肠癌患者中，高CONUT评分与低CONUT评分相比，术后并发症的可能性更大（HR 2.04, 95% CI 1.44-2.89, p < 0.0001）。结论：本研究提示CONUT评分在预测结直肠癌患者短期和长期预后方面的预后能力；因此，它可以被常规计算以对患者的风险进行分层。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Colorectal Disease 医学-胃肠肝病学

CiteScore

6.10

自引率

11.80%

发文量

406

审稿时长

1.5 months

期刊介绍： Diseases of the colon and rectum are common and offer a number of exciting challenges. Clinical, diagnostic and basic science research is expanding rapidly. There is increasing demand from purchasers of health care and patients for clinicians to keep abreast of the latest research and developments, and to translate these into routine practice. Technological advances in diagnosis, surgical technique, new pharmaceuticals, molecular genetics and other basic sciences have transformed many aspects of how these diseases are managed. Such progress will accelerate. Colorectal Disease offers a real benefit to subscribers and authors. It is first and foremost a vehicle for publishing original research relating to the demanding, rapidly expanding field of colorectal diseases. Essential for surgeons, pathologists, oncologists, gastroenterologists and health professionals caring for patients with a disease of the lower GI tract, Colorectal Disease furthers education and inter-professional development by including regular review articles and discussions of current controversies. Note that the journal does not usually accept paediatric surgical papers.